Founder, Chairman & CEO
“It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is most adaptable to change.“ – Charles Darwin
Prior to founding Biomea Fusion in 2017, Ramses and Tom built-up Point Sur Investors, a long-only biotech investment fund focused solely on innovative therapies that significantly improve the standard of care where Tom serves as Managing Partner. Before forming Biomea, Tom managed Investor Relations at Pharmacyclics Inc., where he helped grow the company from a market cap of $6.74B to over $21B, which included the execution of one of the largest biotech acquisitions to date. Prior to Pharmacyclics, Inc., Tom spent 6 years as a medicinal chemist at Gilead Sciences Inc. engaging in novel drug design and drug development of HCV polymerase and protease inhibitors. Tom holds an M.B.A. from the University of California Los Angeles (2012) and a master’s degree in Organic Chemistry from the University of California Santa Barbara (2007). As a research scientist, Thomas Butler has been awarded numerous patents in the U.S. and internationally, as well as published in top academic journals such as the American Chemical Society Journal of Medicinal Chemistry and Angewandte Chemie.